Education
About Us
Working with TipRanks
Follow Us
Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
Total Valuation
Aprea Therapeutics has a market cap or net worth of $7.64M. The enterprise value is -$5.52M.
Market Cap$7.64M
Enterprise Value-$5.52M
Share Statistics
Aprea Therapeutics has 6,310,673 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,310,673
Owned by Insiders11.83%
Owned by Institutions11.20%
Financial Efficiency
Aprea Therapeutics’s return on equity (ROE) is -0.67 and return on invested capital (ROIC) is -69.45%.
Return on Equity (ROE)-0.67
Return on Assets (ROA)-0.54
Return on Invested Capital (ROIC)-69.45%
Return on Capital Employed (ROCE)-0.69
Revenue Per Employee187.82K
Profits Per Employee-1.62M
Employee Count8
Asset Turnover0.06
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aprea Therapeutics is ―. Aprea Therapeutics’s PEG ratio is 0.03.
PE Ratio―
PS Ratio12.06
PB Ratio0.94
Price to Fair Value0.94
Price to FCF-1.34
Price to Operating Cash Flow-0.56
PEG Ratio0.03
Income Statement
In the last 12 months, Aprea Therapeutics had revenue of 1.50M and earned -12.96M in profits. Earnings per share was -2.35.
Revenue1.50M
Gross Profit-7.86M
Operating Income-14.32M
Pretax Income-12.96M
Net Income-12.96M
EBITDA-14.30M
Earnings Per Share (EPS)-2.35
Cash Flow
In the last 12 months, operating cash flow was -13.44M and capital expenditures 0.00, giving a free cash flow of -13.44M billion.
Operating Cash Flow-13.44M
Free Cash Flow-13.44M
Free Cash Flow per Share-2.13
Dividends & Yields
Aprea Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.76
52-Week Price Change-59.40%
50-Day Moving Average1.44
200-Day Moving Average1.86
Relative Strength Index (RSI)37.04
Average Volume (3m)55.77K
Important Dates
Aprea Therapeutics upcoming earnings date is Mar 26, 2026, After Close (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Aprea Therapeutics as a current ratio of 7.01, with Debt / Equity ratio of 0.00%
Current Ratio7.01
Quick Ratio7.01
Debt to Market Cap0.00
Net Debt to EBITDA1.77
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aprea Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aprea Therapeutics EV to EBITDA ratio is 0.37, with an EV/FCF ratio of 0.35.
EV to Sales-3.14
EV to EBITDA0.37
EV to Free Cash Flow0.35
EV to Operating Cash Flow0.35
Balance Sheet
Aprea Therapeutics has $13.72M in cash and marketable securities with $0.00 in debt, giving a net cash position of $13.72M billion.
Cash & Marketable Securities$13.72M
Total Debt$0.00
Net Cash$13.72M
Net Cash Per Share$2.17
Tangible Book Value Per Share$3.50
Margins
Gross margin is 120.74%, with operating margin of -953.00%, and net profit margin of -862.43%.
Gross Margin120.74%
Operating Margin-953.00%
Pretax Margin-862.43%
Net Profit Margin-862.43%
EBITDA Margin-860.94%
EBIT Margin-862.43%
Analyst Forecast
The average price target for Aprea Therapeutics is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.00
Price Target Upside726.45% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-62.75%
EPS Growth Forecast23.87%